期刊文献+

不同分子亚型乳腺癌中癌干细胞量的研究 被引量:2

Prognostic value of different amounts of cancer stem cells in different molecular subtypes of breast cancer
原文传递
导出
摘要 目的研究乳腺癌不同分子亚型中癌干细胞量的差别。方法根据分子亚型将乳腺癌组织标本分为A(乳腺腔内A型),B(乳腺腔内B型),C(HER-2过表达型),D(基底样型),E(正常细胞样型)5组,通过集落细胞法计数各组癌干细胞球,分析乳腺癌干细胞量与乳腺癌不同分子亚型的关系。结果 A,B两组的癌干细胞球数分别为(1.1±0.2)/1 000细胞和(1.3±0.1)/1 000细胞,组间差异无统计学意义(P>0.05);C组的癌干细胞球数为(8.6±1.0)/1 000细胞,明显多于A,B组(均P<0.05);D,E两组的癌干细胞球数分别为(22.4±1.2)/1 000细胞和(17.7±2.0)/1 000细胞,两组间差异无统计学意义(P>0.05),但均明显多于前3组(均P<0.05)。结论不同分子亚型乳腺癌组织中含有不同量的癌干细胞,对预测乳腺癌预后可能有一定意义。 Objective To investigate the differences in the amount of cancer stem cells in difirent breast cancer subtypes. Methods The specimens of breast cancer tissues were divided into five groups: group A (luminal A type), B (luminal B type), C (HER2 + type), D (basal-like type) and E (normal-like) according to their molecular subtypes. The cancer stem cell spheres in each group were measured through colony formation method, and then the relations of the amount of cancer stem eells with the subtypes of breast cancer were analyzed. Results The numbers of cancer stem cell spheres in group A and B were ( 1. 1 ± 0.2)/1 000 cells and (1. 3 ±0. 1 )/1 000 cells, respectively, and this had no significant difference (P〉0.05). The number of cancer stem cell spheres in group C was (8. 6 ±1.0)/1 000 cells, which was significantly higher than that in group A and B ( both P 〈 0. 05 ) . The numbers of cancer stem cell spheres in group D and E were (22. 4 ± 1. 2 )/1 000 cells and ( 17. 7 ± 2. 0 )/1 000 cells, respectively, and this was statistically similar ( P 〉 0.05 ) but either was significantly higher than that in the other three groups ( all P 〈 0. 05 ) . Conclusions Breast caucer tissues of different molecular subtypes contain varying amounts of cancer stem cells, and this may have certain significance for predicting the prognosis of breast cancer.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2011年第11期1208-1211,共4页 China Journal of General Surgery
基金 福建省卫生厅青年基金项目资助(2010K737)
关键词 乳腺肿瘤 分子亚型 肿瘤干细胞 预后 Breast Neoplasms Molecular Subtype Neoplastic Stem Cells Prognosis
  • 相关文献

参考文献4

  • 1Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome [ J ] . (Jell Stem Cell, 2007, 1(5) :555 -567.
  • 2Vassilopoulos A, Wang RH, Pctrovas C, et al. Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells[ J ]. Int J Biol Sci, 2008, 4(3) : 133 - 142.
  • 3李治,刘春萍,贺艳丽,张景辉,黄韬.乳腺癌干细胞多药耐药基因的表达及意义[J].肿瘤,2008,28(2):129-131. 被引量:14
  • 4于超,吴诚义.Basal-like型乳腺癌的研究进展[J].中国普通外科杂志,2009,18(5):498-501. 被引量:2

二级参考文献39

  • 1Reis-Filho JS, Milanezi F, Steele D et al. Metaplastic breastcarcinomas are basal-like tumours [ J ] . Histopathology ,2006,49 ( 1 ) : 10 - 21.
  • 2Collett K, StefanssonlM, Eide J, et al. A basal epithelial phenotype is frequent in interval breast cancers compared with screen detected tumors [ J ]. Cancer Epidemiol Biomarkers Prey, 2005, 14 ( 5 ) : 1108 -1112.
  • 3Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade Ⅲ invasive ductal carcinoma of the breast: pattern s of metastasis and long-term survival [ J ] . Breast Cancer Res, 2007,9(1) :4-11.
  • 4Turner NC, Reis-Filho JS. Basal- like breast cancer and the BRCA1 phenotype[J]. Oncogene, 2006 , 25(43) :5846 -5853.
  • 5Rakha EA, El- Sayed ME, Green AR, et al. Prognostic markers intriplenegative breast cancer [ J ]. Cancer,2007,109(1) :25 -32.
  • 6Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence [ J ]. Clin Cancer Res, 2007,13 ( 15 Pt 1 ) : 4429 - 4434.
  • 7Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy [ J ]. Clin Cancer Res,2005, 11 (16): 5678 - 5685.
  • 8Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer [ J ]. Cancer, 2007, 109 ( 1 ) : 25 - 32.
  • 9Van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome [ J ] . Am J Pathol, 2002, 161 (6) :1991 -1996.
  • 10Dolled-Filhart M, Ryden L, Crego ger M, et al. Classification of breast cancer using genetic algorithms and tissue microarrays [ J ]. Clin Cancer Res, 2006, 12 ( 1 ) : 6459 - 6468.

共引文献14

同被引文献18

  • 1周东风,李红梅.47例原发性乳腺癌多药耐药MDR1基因表达及其临床意义[J].肿瘤学杂志,2005,11(1):29-30. 被引量:5
  • 2Sun JG, Liao RX, Qiu J, et al. Microarray-based analysis of microRNA expression in breast cancer stem cells [J]. J Exp Clin Cancer Res, 2010, 29(3): 174.
  • 3Guo J, Zhou J, Ying X, et al. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells[J]. J pharm pharmac Sci, 2010, 13(2): 136-51.
  • 4Phillips TM, Mcbride WH, Pajonk F. The response of CD24(-/low)/ CD44+ breast cancer-initiating cells to radiation[J]. J Natl Cancer Inst, 2006, 98(24): 1777-85.
  • 5Pleban K, Kopp S, Csaszar E, et al. P-glycoprotein substrate binding domains are located at the transmembrane domain/transm-embrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach[J]. Mol Pharmacol, 2005, 67 (2): 365-74.
  • 6Rosenberg MF, Callaghan R, Modok S, et al. Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state [J]. J Biol Chem, 2005, 280(4): 2857-62.
  • 7Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer[J]. FEBS Lett, 2006, 580(12): 2903-9.
  • 8Bergman AM, Pinedo HM, Talianidis I, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines [J]. Br J Cancer, 2003, 88(12): 1963-70.
  • 9Al-Hajj M, Wicha MS, Benito-Hemandez A, et al. Prospective identification of tumorigenic breast cancer cells [J]. Proc Natl Acad Sci USA, 2003, 100(7): 3983-8.
  • 10Harmahan D,Weinberg RA.The halmarks of cancer [J]. Cell, 2000, 100(1): 57-70.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部